• This strategic partnership brings an innovative intravenous iron replacement therapy to Ecuador, the Dominican Republic, Guatemala, Chile, Panama and soon in Costa Rica — offering a safe and effective treatment alternative for patients.
• The expanded collaboration is a significant step forward in tackling the widespread issue of iron deficiency in the region, and it strengthens SteinCares’ position as a reliable partner for international companies looking to access the Latin American market.

San Jose, Costa Rica, May 2025. SteinCares, a leading specialty healthcare company in Latin America, and Pharmacosmos, a leading international company that specializes in iron treatments have announced the launch of Monofer®—an innovative intravenous iron replacement therapy for those with a deficiency of this mineral—to six new markets: Ecuador, Dominican Republic, Guatemala, Chile, Panama, and Costa Rica*. The strategic partnership reinforces SteinCares’ commitment to providing high-quality, cost-effective treatments and its role as a bridge between global specialty care developments and Latin America’s unmet healthcare needs.

Monofer® is now available to a broader patient population in Latin America—those with iron deficiency, with or without anemia—across key therapeutic areas, including nephrology, cardiology, onco-hematology, gastroenterology, gynecology, and obstetrics, among others.

“Our alliance with Pharmacosmos strengthens our role as the bridge between innovative global therapies and local healthcare needs. Together, we’re setting a new standard for what accessible, high-impact care can look like in the region.”, says Sebastian Katz, Chief Strategy Officer at SteinCares”.

“We see Latin America as a key region where Monofer® can truly make a difference”, added Claes C Strom, Chief Commercial Officer at Pharmacosmos. “Partnering with SteinCares allows us to accelerate that impact—leveraging their strong local presence and healthcare track-record to bring a proven solution to more patients, faster. We are focused on more than market expansion; we want to make innovative and cost-effective healthcare possible”.

Monofer® offers a unique, patient-centered approach to treating iron deficiency. Its high-dose, single-infusion formulation provides faster symptom relief with fewer side effects and logistical challenges, reducing the number of infusions required and improving the overall patient experience. This also translates into cost savings for both healthcare systems and through reduced hospital visits and operational burden.

To ensure the successful launch, SteinCares implemented a comprehensive strategy focused on continued medical education, empowering healthcare professionals and nursing staff with the training needed to address iron deficiency more effectively.

About SteinCares  

SteinCares is a leader in the commercialization and distribution of specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.  

For more information, visit http://www.steincares.com/ or follow the company on LinkedIn.  

About Pharmacosmos

PharmaCosmos is a leading company based in Denmark, with a track record of more than 50 years of innovation in iron and carbohydrate-based treatments and solutions for human and animal use. They have an R&D program focused on research and improving the quality of life of patients.

The company has affiliates in the Nordic countries, the United Kingdom and the United States, with products marketed in more than 80 countries around the world. Its manufacturing facilities are approved by regulatory authorities such as the Danish Medicines Agency and the U.S. FDA to ensure high quality products.

For more information, visit https://pharmacosmos.com/